Longevity & Metabolism

Immunis's secretome therapy showed 26% gait speed improvement in sarcopenic seniors, validating a longevity platform that sidesteps FDA's refusal to recognize aging as disease.

The Swedish biotech's LIB-01 offers eight-week efficacy from three-day dosing, targeting high discontinuation rates with current PDE5 inhibitors.

Gero AI has secured major pharma partnerships in aging space despite raising only $17M, punching well above its weight class.

A new CEO, a passionate founder, early-stage R&D and hopes of an IPO – can Swiss biotech Topadur find success?

The biopharmaceutical landscape in 2026 will be shaped by rapid technological progress, shifting geographic leadership, a looming patent cliff and a renewed focus on capital efficiency.

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.

As we enter 2025, In Vivo convened a group of biotech executives for a wide-ranging conversation about dealmaking this year and the challenges and opportunities for companies in the cardiometabolic, longevity, radiopharmaceuticals and cancer spaces. Essential listening before JPM.

InSilico Medicine hopes its open-source LLM will be the “one model to guide them all” as industry moves towards artificial biomedical intelligence and interest in longevity grows.